Hypothalamic Function Before and After Bariatric Surgery

December 20, 2012 updated by: Mirjam Anne Lips, Leiden University Medical Center

Hypothalamic Morphology, Neuronal Activity and Systems Biology in Response to Food Intake in Obese Patients With Type 2 Diabetes Mellitus Compared to Obese and Lean Controls

The purpose of this study is to determine the effect of gastric banding or gastric bypass on hypothalamic morphology and function, gut hormones and systems biology in obese subjects with and without type 2 diabetes.

Study Overview

Study Type

Observational

Enrollment (Actual)

48

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Zuid Holland
      • Leiden, Zuid Holland, Netherlands, 2333 ZA
        • Leiden University Medical Centre

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

35 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Sampling Method

Probability Sample

Study Population

Obese (type 2 diabetic or not) population from primary care (dietary intervention) and hospital setting (bariatric surgery)

Description

Inclusion Criteria:

  • Patients aged 35-65 years;
  • BMI > 40 kg/m2;
  • BMI > 35 and <40 kg/m2 with co-morbidity, which is expected to improve after surgically-induced weight loss;
  • A history of longstanding obesity (>5 years);
  • Proven failed attempts to lose weight in a conventional way, or primarily successful weight loss with eventual weight regain;
  • Intention to adhere to a postoperative follow-up programme.

Exclusion Criteria:

  • BMI> 50 or body weight > 150 kg (because it is impossible to safely put people above this weight on a standard table for MRI);
  • Subjects with disease related obesity, i.e. Cushing or medication related obesity;
  • Use of medication known to affect glucose or lipid metabolism (i.e. prednisone)
  • Monogenetic diabetes: MODY, Mitochondrial diabetes;
  • LADA (adult-onset latent autoimmune diabetes); detected by c-peptide measurement on screening.
  • Impaired renal function (serum creatinine > 176 μmol/L);
  • Leg ulcers, gangrene.
  • Any genetic or psychiatric disease (e.g. fragile X syndrome, major depression) affecting the brain
  • Any significant chronic disease
  • Renal or hepatic disease
  • Pregnancy
  • Recent weight changes or attempts to loose weight (> 3 kg weight gain or loss, within the last 3 months)
  • Aerobic exercise more that 3 times 60 minutes a week
  • Alcohol consumption of more than 28 units per week at present or in the past
  • Recent blood donation (within the last 2 months)
  • Recent participation in other research projects (within the last 3 months), participation in 2 or more projects in one year
  • Contra-indications to operative procedures as regular in bariatric surgery
  • Contra-indications to MRI scanning

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
obesity diabetes, surgical and dietary
Standard RYGB and LAGB procedures
3 months of using the prodimed diet

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Changes in gut hormones
Time Frame: 3 weeks
3 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Hanno Pijl, MD Phd Proff, Leiden University Medical Centre

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2009

Primary Completion (Actual)

February 1, 2011

Study Completion (Actual)

May 1, 2012

Study Registration Dates

First Submitted

July 21, 2010

First Submitted That Met QC Criteria

July 21, 2010

First Posted (Estimate)

July 22, 2010

Study Record Updates

Last Update Posted (Estimate)

December 24, 2012

Last Update Submitted That Met QC Criteria

December 20, 2012

Last Verified

December 1, 2012

More Information

Terms related to this study

Other Study ID Numbers

  • P08-215

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity

Clinical Trials on Roux en Y gastric bypass and lap. gastric banding

Subscribe